Three years ago this month I started this LifeSciVC blog experiment and its been more fun and rewarding than I would have expected. As I wrote in my first post, the reasons I started blogging were to add a voice from the biotech venture community to the tech-dominated blogosphere, share a data-informed perspective about life science market dynamics and strategies, and leverage the power of social media to connect and communicate with others.
Those reasons still hold today, and I’d encourage others to give it a shot. We still need more voices, and there are too many folks in the biotech venture and startup community that remain largely on the sidelines in the social media arena. Blogging presents an opportunity to share perspectives, foster healthy debate, and improve the overall intellectual robustness of our sector. It also opens up a medium to communicate with a broader set of constituents: beyond bioentrepreneurs and other investors, blogging can reach pundits, reporters, analysts, academics, students, Pharma exec’s, LPs, and many others. To date, LifeSciVC has had over 400K visitors across the site and Forbes postings, as I mentioned in this “Best of” post a few months ago.
So it’s with that sentiment in mind, and a desire to expand the reach and diversity of the content on this blog, that I’ve enlisted a crew of entrepreneurs from Atlas’ friends & family to join this blog as contributors and share their view “From the Trenches” of the startup world (new tab above forthcoming).
Here’s the Atlas biotech gang of eight:
Mike Gilman: Atlas EIR; CEO, Padlock Therapeutics; former CEO, Stromedix- Katrine Bosley: Broad Institute EIR; former CEO, Avila Therapeutics
- Jonathan Montagu: CBO, Nimbus Discovery
- Bill Marshall: CEO, MiRagen Therapeutics
- Kevin Pojasek: Atlas EIR; COO, Annovation and COO, Quartet Medicine
- Ankit Mahadevia: Atlas EIR; CBO, Rodin Therapeutics and CBO, Spero Therapeutics
- Jeff Hatfield: CEO, Vitae Pharmaceuticals
- Tom Hughes: CEO, Zafgen
These eight contributors will likely over a wide-range of topics – from different startup strategies and management philosophies, to specific practical and tactical observations of what works and what doesn’t. Perhaps what VCs they actually like and don’t like (ok, maybe not that one). Hopefully, they’ll each have time to generate a few pieces a year to toss into the mix.
In some ways, this is Part 2 of this blog’s experiment – if it works and adds something to the ecosystem, we’ll keep doing it. If not, we’ll move on and stay focused on our day jobs. Feedback much appreciated.
Expect Mike’s first one on Monday morning.